CPU0213, an endothelin receptor antagonist, alleviates diabetic car-diomyopathy through suppressing NADPH oxidase in rats

Abstract

Abstract: AIM: To study the activation of NAD-PH oxidase in diabetic cardiomyopathy participates in myocardial injury that is likely reversed by an endothe-lin receptor antagonist CPU0213.METHODS: Male SD rats were administrated STZ (60mg^。kg^-1 ^。d^-1,i.p.) to develop diabetes mellitus for 8 weeks. CPU0213 (100 mg/kg, p.o .) and aminoguanidine (AMI, 100 mg/kg, p.o .) were applied for 4 weeks. RESULTS: CPU0213 and AMI could significantly al-leviate myocardial hypertrophy, reduce the level of ET-1 and oxidative stress except blood glucose in diabetic rats.Over-expression of mRNA and protein of p22phox and p67phox in neonatal SD rats myocytes incubated with high glucose was suppressed by both CPU0213 and AMI.CONCLUSION: Endothelin receptor antagonist CPU0213 and AMI alleviated diabetic cardiomyopathy in rats, mediated by suppressing over-expression of NADPH oxidase in the myocardium .

Key words: diabetes, oxidase stress, NADPH ox-idase, CPU0213

CLC Number:

R965.1

XU Ming , JI Hui, DAI De-zai, SHI Yan-ping, DAI Yin. CPU0213, an endothelin receptor antagonist, alleviates diabetic car-diomyopathy through suppressing NADPH oxidase in rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(10): 1086-1090.

References

[1] Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy : a short re-view[J] .Mol Cell Biochem, 2004, 261(12) :187-191.
[2] Murdoch CE, Zhang M, Cave AC, et al. NADPH oxi-dase-dependent redox signalling in cardiac hypertrophy, remodelling and failure[J] .Cardiovasc Res, 2006, 71 (2) :208-215.
[3] Guo Z, Xia Z, Jiang J, et al. Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl -L-cysteine[J] .Am J Physiol Heart Circ Physiol, 2007, 292(4) :H1728-1736.
[4] He HB, Dai DZ, Dai Y. CPU0213, a novel endothelin receptor antagonist, ameliorates septic renal lesion by sup-pressing ET system and NF-kappaB in rats[J] .Acta Phar-macol Sin, 2006, 27(9) :1213-1221.
[5] Jandeleit-Dahm K, Cooper ME. The role of AGEs in car-diovascular disease[J] .Curr Pharm Des, 2008, 14(10) : 979-986.
[6] Quehenberger P, Bierhaus A, Fasching P, et al. Endo-thelin 1transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells[J] .Diabe-tes, 2000, 49(9) :1561-1570.
[7] Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy :a short re-view[J] .Mol Cell Biochem, 2004, 261(12) :187-191.
[8] Etoh T, Inoguchi T, Kakimoto M, et al. Increased ex-pression of NAD (P) H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibility by interventive insulin treatment [J] .Diabetologia, 2003, 46(10) :1428-1437.
[9] Su W, Dai DZ, Liu HR, et al. Upregulated endothelin system in diabetic vascular dysfunction and early retinopa-thy is reversed by CPU0213 and total triterpene acids from Fructus Corni[J] .Clin Exp Pharmacol Physiol, 2007, 34 (12) :1228-1233.
[10] Callera GE, Tostes RC, Yogi A, et al.Endothelin-1-in-duced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms[J] .Clin Sci (Lond), 2006, 110(2) :243-253.
[11] Duda M, Konior A, Klemenska E, et al. Preconditioning protects endothelium by preventing ET-1-induced activation of NADPH oxidase and xanthine oxidase in post-ischemic heart[J] .J Mol Cell Cardiol, 2007, 42(2) :400-410.
[12] Qi MY, Xia HJ, Dai DZ, et al. A novel endothelin re-ceptor antagonist CPU0213 improves diabetic cardiac insuf-ficiency attributed to up-regulation of the expression of FK-BP12.6, SERCA2a, and PLB in rats[J] .J Cardiovasc Pharmacol, 2006, 47(6) :729-735.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[3]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[4]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[5]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[6]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[7]	DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo. Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
[8]	CAI Jing, PAN Binjing, LIU Jingfang. Research progress on the relationship between hypoglycemic drugs and sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
[9]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[10]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[11]	ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin. Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
[12]	LI Hao, LI Ling, XIA Zhiping, YE Qifa, PENG Guizhu. FXR agonist GW4064 ameliorates tacrolimus-induced abnormalities in glucose metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 466-472.
[13]	SHAO Xi, YU Yanan, HUANG Yuhan, WANG Xiaotong, LING Hongwei, LV Dongmei, WANG Tao. Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 287-294.
[14]	LV Xiaohan, LIN Rong. Association of Lin28 with tumor, cardiovascular disease and diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 205-211.
[15]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.